Related Experiment Video
Updated: Aug 7, 2025
04:37
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
212
What is resistant arterial hypertension?
Evgeniya V Shalaeva1,2, Franz H Messerli3,4
1Division of Public Health Science, Westminster International University in Tashkent, Tashkent, Uzbekistan.
Blood Pressure
|March 9, 2023
Summary
Resistant arterial hypertension (RAH) affects nearly 1 in 6 patients with uncontrolled blood pressure despite optimal medication. Early diagnosis and treatment of RAH are crucial for improving patient outcomes and reducing cardiovascular risks.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Medicine
Background:
- Arterial hypertension affects 1.28 billion adults globally, with over 80% having uncontrolled blood pressure.
- Resistant arterial hypertension (RAH) is a significant clinical challenge, often unrecognized.
Purpose of the Study:
- To define resistant arterial hypertension (RAH).
- To describe RAH prevalence, patient characteristics, risk factors, diagnosis, and prognosis.
- To differentiate RAH from refractory hypertension.
Main Methods:
- Review of current literature on resistant arterial hypertension.
- Definition of RAH: elevated blood pressure despite ≥3 antihypertensive classes (including CCB, RAS inhibitor, thiazide diuretic) at maximal doses.
- Prevalence estimation: RAH occurs in approximately 1 in 6 hypertensive patients.
Main Results:
- RAH is characterized by uncontrolled blood pressure despite triple-therapy.
- Underdiagnosis is common due to suboptimal prescribing of antihypertensive medications.
- RAH significantly increases the risk of cardiovascular diseases and mortality.
Conclusions:
- RAH is associated with severe cardiovascular complications and increased mortality.
- Timely diagnosis and management of RAH are essential for mitigating risks.
- Effective treatment strategies can improve both short- and long-term patient prognosis.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
796
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
796
01:29Hypertension II: Pathophysiology
27
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
27
01:25Antihypertensive Drugs: Direct Renin Inhibitors
724
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
724
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
479
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
212
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
212
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
731
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
731